Table 2.
Primary treatment of the whole cohort and the five most frequent tumor entities
| Whole cohort (%) |
Squamous cell carcinoma (%) | Adenocarcinoma (%) |
Melanoma (%) |
Adenoid cystic carcinoma (%) | Esthesio-neuroblastoma (%) | ||
|---|---|---|---|---|---|---|---|
| Total patients | 144 (100) | 74 (100) | 24 (100) | 18 (100) | 9 (100) | 7 (100) | |
| Primary surgery | 29 (20.1) | 17 (23) | 5 (20.8) | 1 (5.6) | 1 (11.1) | 2 (28.6) | |
| Primary surgery + RT | 66 (45.8) | 26 (35.1) | 13 (54.2) | 13 (66.7) | 7 (77.8) | 5 (71.4) | |
| Primary RT alone | 17 (11.8) | 12 (16.2) | 2 (8.3) | 2 (11.1) | 1 (11.1) | 0 | |
| Primary RTCX | 18 (12.5) | 14 (18.9) | 1 (4.2) | 0 | 0 | 0 | |
| Palliative therapy (CX ± RT) | 12 (9.0) | 4 (5.4) | 3 (12.5) | 2 (11.1) | 0 | 0 | |
| Best supportive care | 2 (1.4) | 1 (0.7) | 0 | 0 | 0 | 0 | |
| Margin status after surgery | R0 | 25 (27.5) | 14 (35) | 5 (27.8) | 4 (30.8) | 1 (16.7) | 1 (12.5) |
| R1 | 35 (38.5) | 14 (35) | 5 (27.8) | 4 (30.8) | 5 (83.3) | 3 (37.5) | |
| R2 | 5 (5.5) | 1 (2.5) | 2 (11.1) | 1 (7.7) | 0 | 0 | |
| RX | 26 (28.6) | 11 (27.5) | 6 (33.3) | 4 (30.8) | 0 | 4 (50) | |
RT Radiotherapy, CX Chemotherapy